Indian Immunologicals flags counterfeit Abhayrab vaccine seizure in Delhi
Indian Immunologicals said counterfeit Abhayrab rabies-vaccine vials seized by Delhi Police were not exported by the company. Four people were arrested, while drug regulators and state controllers were alerted to strengthen distribution-channel surveillance.
What happened
Indian Immunologicals said counterfeit Abhayrab rabies vaccine vials seized in Delhi were not exported. Authorities arrested four people, alerted state drug
Key facts
- Batch No. KE25012
- 4 people arrested
- 40% market share in India
- Rs 300-390 per dose
- Supplied to 43 countries
- Previous fake batch identified in January 2025
Why this matters
The incident increases the strategic value of partnerships or acquisitions in serialization, track-and-trace, authenticated dispensing, and regulated cold-chain distribution capabilities.
What to watch
- Regulatory notices naming counterfeit batch numbers, packaging markers, affected geographies, or formal recall instructions.
- Further police seizures, arrests, or evidence that counterfeit stock entered licensed pharmacies or hospitals.
- Reports of treatment failures, adverse events, or patient exposure tied to suspect vials.
- Changes in Abhayrab availability, distributor allocation, hospital procurement patterns, or pharmacy out-of-stock rates.
- Company deployment of QR, serialization, tamper-evident packaging, or other traceability measures.
- State drug-controller inspection intensity beyond Delhi and any license suspensions involving wholesalers or retailers.
- Quarantine and authenticate Abhayrab inventory using batch, packaging, invoice, and authorized-distributor checks before dispensing.
- Require pharmacies and hospitals to document supplier provenance and immediately report suspect vials to drug-control authorities and the manufacturer.
- Indian Immunologicals is likely to publish lot-identification guidance, reinforce authorized-channel messaging, and coordinate with regulators on field verification.
- Distributors may reduce purchases from secondary wholesalers, increase direct procurement, and seek faster replenishment of verified inventory.
- Large hospital chains and vaccine retailers may temporarily add alternative approved rabies-vaccine suppliers to protect continuity of post-exposure treatment.